Merck is a buy. The stock is breaking out technically on positive oncology pipeline news, with Keytruda combination therapies extending its franchise ahead of patent expirations. Despite a premium valuation (P/E 33.9 vs peer median 23.5), strong earnings recovery, a 5-year revenue CAGR of ~7.5%, and a sharp increase in smart money accumulation (score 0.2888 in Q1 2026) support further upside. The dividend and defensive healthcare profile add appeal.
Keytruda Patent Cliff
Keytruda patents expire later this decade, threatening a significant portion of revenue and profits.
Gardasil Weakness
Gardasil sales are declining due to weak demand in China and inventory issues, clouding the vaccine segment outlook.
Elevated Leverage
Total debt jumped to $50.5B in 2025 from $38.3B in 2024, raising financial risk if cash flows weaken.
Valuation Compression
MRK trades at a 44% P/E premium to peers; any growth disappointment could lead to multiple contraction.